<DOC>
	<DOCNO>NCT00000993</DOCNO>
	<brief_summary>To prevent individual massive accidental exposure HIV become infect HIV possibly develop AIDS , treat zidovudine ( AZT ) . Although number person ( ) expose high concentration HIV quite small , person high risk become infected treatment need prevent infection exposure . In animal study , AZT prevent development infection exposure animal retrovirus ( HIV retrovirus ) . In patient AIDS , AZT effective delay progression disease . For reason trial AZT indicate .</brief_summary>
	<brief_title>A Study Zidovudine Prevention HIV Infection Individuals Exposed Virus</brief_title>
	<detailed_description>Although number person ( ) expose high concentration HIV quite small , person high risk become infected treatment need prevent infection exposure . In animal study , AZT prevent development infection exposure animal retrovirus ( HIV retrovirus ) . In patient AIDS , AZT effective delay progression disease . For reason trial AZT indicate . Persons accept study take AZT capsule every 4 hour ( 6 time daily ) 42 day . Treatment AZT start soon possible , later 5 day , exposure HIV . Blood urine sample various study take interval 42-day treatment period , blood sample take every 3 month 1 year every 6 month 2 year test sign HIV infection ( HIV antibody determination ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Participant must HIVnegative entry source must HIVpositive . The source document infected HIV one follow criterion : Clinical diagnosis AIDS ARC . Positive test HIV antibody ( ELISA Western blot ) presence HIV p24 antigen serum . Participant may enrol source exposure suspect infected HIV ( member risk group , type symptom HIV infection ) , source must confirm infected HIV participant remain study . Significant exposure within 5 day prior begin therapy , define one following : Research laboratory worker auxiliary personnel , course work , expose high titer virus abrade skin mucous membrane accidentally inoculate high titer cellassociated free virus expose wound puncture . Organ transplant recipient HIVpositive donor . Recipients blood blood product HIVpositive donor . Women artificially inseminate semen HIVpositive donor . Other source exposure consider appropriate principal investigator sponsor . Persons poor health ( renal , hepatic , bone marrow insufficiency ) evaluate casebycase basis . Exclusion Criteria Prior Medication : Excluded within 4 week study entry : Treatment potentially myelosuppressive drug . Nephrotoxic agent . Other experimental therapy . Prior Treatment : Excluded within 1 month study entry : Blood transfusion evidence compromise blood marrow function . Patients may follow : History malignancy cutaneous basal cell cervical carcinoma . Significant , chronic underlie medical illness , physician 's judgment , would impair study completion . Liver dysfunction bilirubin &gt; 5 x ULN , alkaline phosphatase &gt; 5 x upper limit normal , SGPT &gt; 5 x upper limit normal . Compromised bone marrow function hemoglobin &lt; 11 g/dl blood transfusion within last month , granulocytes &lt; 1500 cells/mm3 , platelet &lt; 100000/mm3 . When possible , concomitant medication administer treatment period . Prior diagnosis HIV infection one follow criterion : HIV antibody positive ELISA Western blot assay . HIV p24 antigen positive . Clinical symptom lead diagnosis license physician AIDS / AIDS relate complex ( ARC ) / AIDS dementia . Active drug alcohol abuse sufficient investigator ' opinion prevent compliance study regimen .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1991</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Accidents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS Serodiagnosis</keyword>
	<keyword>Zidovudine</keyword>
</DOC>